Evaluation of Effectiveness of KDR2-2 Suspension Eyedrop on Neovascular Regression in the Treatment of Neovascular Glaucoma: an Exploratory Clinical Trial
Latest Information Update: 16 Dec 2024
Price :
$35 *
At a glance
- Drugs KDR2-2 (Primary)
- Indications Neovascular glaucoma
- Focus Therapeutic Use
- Acronyms KDR-NVG
- 11 Dec 2024 Planned End Date changed from 28 Feb 2022 to 31 Dec 2024.
- 11 Dec 2024 Planned primary completion date changed from 31 Jan 2022 to 31 Dec 2024.
- 11 Dec 2024 Status changed from recruiting to active, no longer recruiting.